A frame from the final video containing human-hearable audio track showing grooming behavior and FM USV call at frame #50. by Piotr Popik (292215)

EphA4 immunostaining is decreased adjacent to injury site in ephrin-A5-Fc treated mice. by Yona Goldshmit (205708)

“…Arrows indicate lesion site. Scale bars in A–D, G,H, 100 µm; E,F, 50 µm.</p>…”

SUVmax and SUVmean for each hot sphere when the Gaussian filter is changed. by Masakazu Tsujimoto (22339504)

Subjects:

BKM120 decreases cellular glycolytic metabolic activity in MB cell lines. by Ping Zhao (47228)

EQI decreases malonyl-CoA levels in <i>S</i>. <i>aureus</i>. by Erica C. Larson (1344687)

Datasets used in the study area. by Zhen Zhao (159931)

“…Firstly, recursive feature elimination using cross validation (RFECV), maximum information coefficient (MIC), and mean decrease accuracy (MDA) methods were utilized to select population distribution feature factors. …”

Fig 13 - by Jianbo Jia (717814)

The process of selecting participants. by Na Li (6550)

“…The OS and CSS rates were 76.44% and 72.99% for all patients, respectively. There was a significant decreasing trend in the incidence [average annual percent change (AAPC) = -2.3, 95% confidence interval (CI): -3.9, -0.7], all-cause mortality (AAPC = -12.8, 95% CI: -15.6, -9.9) and specific mortality (AAPC = -13.0, 95% CI: -16.1, -9.8) rate of liver metastases in ovarian cancer. …”

C-indexes for the nomograms. by Na Li (6550)

“…The OS and CSS rates were 76.44% and 72.99% for all patients, respectively. There was a significant decreasing trend in the incidence [average annual percent change (AAPC) = -2.3, 95% confidence interval (CI): -3.9, -0.7], all-cause mortality (AAPC = -12.8, 95% CI: -15.6, -9.9) and specific mortality (AAPC = -13.0, 95% CI: -16.1, -9.8) rate of liver metastases in ovarian cancer. …”

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Fig 6 - by Felix Bosch (10024550)

Molecular Insight into the Growth of Hydrogen and Methane Binary Hydrates by Zhengcai Zhang (2235856)

“…We find that there is a maximum growth rate of H₂ + CH₄ binary hydrates at 250 K when the pressure is 50 MPa, and at fixed temperature, the growth rate of H₂ + CH₄ binary hydrates shows a positive correlation with pressure. …”

Fig 5 - by Felix Bosch (10024550)